These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 25433146)

  • 1. An algebraic model for the kinetics of covalent enzyme inhibition at low substrate concentrations.
    Kuzmič P; Solowiej J; Murray BW
    Anal Biochem; 2015 Sep; 484():82-90. PubMed ID: 25433146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid Determination of the Specificity Constant of Irreversible Inhibitors (kinact/KI) by Means of an Endpoint Competition Assay.
    Miyahisa I; Sameshima T; Hixon MS
    Angew Chem Int Ed Engl; 2015 Nov; 54(47):14099-102. PubMed ID: 26426864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An algebraic model to determine substrate kinetic parameters by global nonlinear fit of progress curves.
    Reytor González ML; Cornell-Kennon S; Schaefer E; Kuzmič P
    Anal Biochem; 2017 Feb; 518():16-24. PubMed ID: 27823930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Half-time analysis of the kinetics of irreversible enzyme inhibition by an unstable site-specific reagent.
    Topham CM
    Biochim Biophys Acta; 1988 Jun; 955(1):65-76. PubMed ID: 3382673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Perspective on the Kinetics of Covalent and Irreversible Inhibition.
    Strelow JM
    SLAS Discov; 2017 Jan; 22(1):3-20. PubMed ID: 27703080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of Ki in a competitive enzyme-inhibition model: comparisons among three methods of data analysis.
    Kakkar T; Boxenbaum H; Mayersohn M
    Drug Metab Dispos; 1999 Jun; 27(6):756-62. PubMed ID: 10348808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Slow-binding inhibition of gamma-aminobutyric acid aminotransferase by hydrazine analogues.
    Lightcap ES; Silverman RB
    J Med Chem; 1996 Feb; 39(3):686-94. PubMed ID: 8576911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding modes of 6,7 di-substituted 4-anilinoquinoline-3-carbonitriles to EGFR.
    Akula N; Bhalla J; Sridhar J; Pattabiraman N
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3397-400. PubMed ID: 15177440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases.
    Singh J; Dobrusin EM; Fry DW; Haske T; Whitty A; McNamara DJ
    J Med Chem; 1997 Mar; 40(7):1130-5. PubMed ID: 9089334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calculation of inhibitor Ki and inhibitor type from the concentration of inhibitor for 50% inhibition for Michaelis-Menten enzymes.
    Brandt RB; Laux JE; Yates SW
    Biochem Med Metab Biol; 1987 Jun; 37(3):344-9. PubMed ID: 3606895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of enzyme inhibition data in screening for new drugs.
    Bush K
    Drugs Exp Clin Res; 1986; 12(6-7):565-76. PubMed ID: 3488892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase.
    Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM
    Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simple method for determining kinetic constants of complexing inactivation at identical enzyme and inhibitor concentrations.
    Wang MH; Zhao KY
    FEBS Lett; 1997 Aug; 412(3):425-8. PubMed ID: 9276440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mode of action of site-directed irreversible folate analogue inhibitors of thymidylate synthase.
    Lobo AP; Nair MG; Changchien L; Weichsel A; Montfort WR; Maley F
    Biochemistry; 1998 Mar; 37(13):4535-42. PubMed ID: 9521774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of substrate inhibition kinetics in enzymatic chemical oscillations.
    Shen P; Larter R
    Biophys J; 1994 Oct; 67(4):1414-28. PubMed ID: 7819481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generalized theoretical and practical treatment of the kinetics of an enzyme-catalyzed reaction in the presence of an enzyme equimolar irreversible inhibitor.
    Golicnik M; Stojan J
    J Chem Inf Comput Sci; 2003; 43(5):1486-93. PubMed ID: 14502482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.
    Lichtner RB; Menrad A; Sommer A; Klar U; Schneider MR
    Cancer Res; 2001 Aug; 61(15):5790-5. PubMed ID: 11479217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissection, Optimization, and Structural Analysis of a Covalent Irreversible DDAH1 Inhibitor.
    Burstein-Teitelbaum G; Er JAV; Monzingo AF; Tuley A; Fast W
    Biochemistry; 2018 Jul; 57(30):4574-4582. PubMed ID: 29983043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Thompson AM; Murray DK; Elliott WL; Fry DW; Nelson JA; Showalter HD; Roberts BJ; Vincent PW; Denny WA
    J Med Chem; 1997 Nov; 40(24):3915-25. PubMed ID: 9397172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.